re: Ann: New Drug Application for AXIRON acce... the one thing that is really unfortunate about ACR is that it's always an uphill battle simply because biotechs are out of favour.
Get yourself a miner with a speculative prospect and the stock will double even when the licence is 12 months out. Rumours of a deal with a bigger player bhp or rio will see it sky rocket, even without details of the deal.
Get yourself a biotech with a proven system, a drug with preliminary approval from FDA, a massive deal with a major player, full details regarding the deal, and what do you get?
a little spike in volumes.
Add to My Watchlist
What is My Watchlist?
